Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated. This study aims to investigate the efficacy of Hyperthermic IntraVesical Chemot...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-02, Vol.15 (5), p.1455 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1455 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Anastay, Vassili Baboudjian, Michael Masson-Lecomte, Alexandra Lebacle, Cédric Chamouni, Alexandre Irani, Jacques Tillou, Xavier Waeckel, Thibaut Monges, Arnaud Duperron, Céline Gravis, Gwenaelle Walz, Jochen Lechevallier, Eric Pignot, Géraldine |
| description | CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated. This study aims to investigate the efficacy of Hyperthermic IntraVesical Chemotherapy (HIVEC) depending on the presence or absence of CIS. This retrospective, multicenter study was conducted between 2016 and 2021. Patients with non-muscle-invasive bladder cancer (NMIBC) with BCG failure received 6-8 adjuvant instillations of HIVEC. The co-primary endpoints were recurrence-free survival (RFS) and progression-free survival (PFS). A total of 116 consecutive patients met our inclusion criteria of whom 36 had concomitant CIS. The 2-year RFS rate was 19.9% and 43.7% in patients with and without CIS, respectively (
= 0.52). Fifteen patients (12.9%) experienced progression to muscle-invasive bladder cancer with no significant difference between patients with and without CIS (2-year PFS rate = 71.8% vs. 88.8%,
= 0.32). In multivariate analysis, CIS was not a significant prognostic factor in terms of recurrence or progression. In conclusion, CIS may not be considered a contraindication to HIVEC, as there is no significant association between CIS and the risk of progression or recurrence after treatment. |
| doi_str_mv | 10.3390/cancers15051455 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10001134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A741740009</galeid><sourcerecordid>A741740009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-f422c2efa61184efec0faf6e88de1ffc725dd0e2ec376feac0a6f378d590ad013</originalsourceid><addsrcrecordid>eNptUktP5SAUJpOZjEZdu5uQzMZZVKFQaFfGadTbxGQW81hKGHrwYlq4A63J_ffS-DYDCwjf43C-HIQOKTlmrCEnRnsDMdGKVJRX1Qe0WxJZFkI0_OOr-w46SOmW5MUYlUJ-RjtMNISUXO6i6y7htvuJNW6Dn6J2vndGTy54PAW82m4gTmuIozO4W_A7SBkfcLuGMSyI3mzx0ar7c95-w9pOEPH39rK40G6YI5zuo09WDwkOHs899Pvi_Fe7Kq5-XHbt2VVheN1MheVlaUqwWlBac7BgiNVWQF33QK01sqz6nkAJhklhQRuihWWy7quG6J5QtodOH3w3898RegPLXwe1iW7UcauCduot4t1a3YQ7RXMslDKeHY4eHWL4N0Oa1OiSgWHQHsKcVClrQZfQ6kz9-o56G-boc38Lq1oypuKFdaMHUM7bkAubxVSdSU4lz5WbzDr-DyvvHnLmwYN1-f2N4ORBYGJIKYJ9bpIStYyFejcWWfHldTbP_KchYPfvw7Mt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785176716</pqid></control><display><type>article</type><title>Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Anastay, Vassili ; Baboudjian, Michael ; Masson-Lecomte, Alexandra ; Lebacle, Cédric ; Chamouni, Alexandre ; Irani, Jacques ; Tillou, Xavier ; Waeckel, Thibaut ; Monges, Arnaud ; Duperron, Céline ; Gravis, Gwenaelle ; Walz, Jochen ; Lechevallier, Eric ; Pignot, Géraldine</creator><creatorcontrib>Anastay, Vassili ; Baboudjian, Michael ; Masson-Lecomte, Alexandra ; Lebacle, Cédric ; Chamouni, Alexandre ; Irani, Jacques ; Tillou, Xavier ; Waeckel, Thibaut ; Monges, Arnaud ; Duperron, Céline ; Gravis, Gwenaelle ; Walz, Jochen ; Lechevallier, Eric ; Pignot, Géraldine</creatorcontrib><description>CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated. This study aims to investigate the efficacy of Hyperthermic IntraVesical Chemotherapy (HIVEC) depending on the presence or absence of CIS. This retrospective, multicenter study was conducted between 2016 and 2021. Patients with non-muscle-invasive bladder cancer (NMIBC) with BCG failure received 6-8 adjuvant instillations of HIVEC. The co-primary endpoints were recurrence-free survival (RFS) and progression-free survival (PFS). A total of 116 consecutive patients met our inclusion criteria of whom 36 had concomitant CIS. The 2-year RFS rate was 19.9% and 43.7% in patients with and without CIS, respectively (
= 0.52). Fifteen patients (12.9%) experienced progression to muscle-invasive bladder cancer with no significant difference between patients with and without CIS (2-year PFS rate = 71.8% vs. 88.8%,
= 0.32). In multivariate analysis, CIS was not a significant prognostic factor in terms of recurrence or progression. In conclusion, CIS may not be considered a contraindication to HIVEC, as there is no significant association between CIS and the risk of progression or recurrence after treatment.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15051455</identifier><identifier>PMID: 36900247</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>BCG ; BCG vaccines ; Bladder cancer ; Cancer ; Cancer therapies ; Care and treatment ; Cellular biology ; Chemotherapy ; Comorbidity ; Disease ; Dosage and administration ; Evaluation ; Hyperthermia ; Immunotherapy ; Invasiveness ; Medical prognosis ; Methods ; Multivariate analysis ; Patients ; Survival ; Urine</subject><ispartof>Cancers, 2023-02, Vol.15 (5), p.1455</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-f422c2efa61184efec0faf6e88de1ffc725dd0e2ec376feac0a6f378d590ad013</citedby><cites>FETCH-LOGICAL-c489t-f422c2efa61184efec0faf6e88de1ffc725dd0e2ec376feac0a6f378d590ad013</cites><orcidid>0000-0001-5282-9134 ; 0000-0001-6935-3873 ; 0000-0002-8215-2918 ; 0000-0002-6321-9144</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001134/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001134/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36900247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anastay, Vassili</creatorcontrib><creatorcontrib>Baboudjian, Michael</creatorcontrib><creatorcontrib>Masson-Lecomte, Alexandra</creatorcontrib><creatorcontrib>Lebacle, Cédric</creatorcontrib><creatorcontrib>Chamouni, Alexandre</creatorcontrib><creatorcontrib>Irani, Jacques</creatorcontrib><creatorcontrib>Tillou, Xavier</creatorcontrib><creatorcontrib>Waeckel, Thibaut</creatorcontrib><creatorcontrib>Monges, Arnaud</creatorcontrib><creatorcontrib>Duperron, Céline</creatorcontrib><creatorcontrib>Gravis, Gwenaelle</creatorcontrib><creatorcontrib>Walz, Jochen</creatorcontrib><creatorcontrib>Lechevallier, Eric</creatorcontrib><creatorcontrib>Pignot, Géraldine</creatorcontrib><title>Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated. This study aims to investigate the efficacy of Hyperthermic IntraVesical Chemotherapy (HIVEC) depending on the presence or absence of CIS. This retrospective, multicenter study was conducted between 2016 and 2021. Patients with non-muscle-invasive bladder cancer (NMIBC) with BCG failure received 6-8 adjuvant instillations of HIVEC. The co-primary endpoints were recurrence-free survival (RFS) and progression-free survival (PFS). A total of 116 consecutive patients met our inclusion criteria of whom 36 had concomitant CIS. The 2-year RFS rate was 19.9% and 43.7% in patients with and without CIS, respectively (
= 0.52). Fifteen patients (12.9%) experienced progression to muscle-invasive bladder cancer with no significant difference between patients with and without CIS (2-year PFS rate = 71.8% vs. 88.8%,
= 0.32). In multivariate analysis, CIS was not a significant prognostic factor in terms of recurrence or progression. In conclusion, CIS may not be considered a contraindication to HIVEC, as there is no significant association between CIS and the risk of progression or recurrence after treatment.</description><subject>BCG</subject><subject>BCG vaccines</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cellular biology</subject><subject>Chemotherapy</subject><subject>Comorbidity</subject><subject>Disease</subject><subject>Dosage and administration</subject><subject>Evaluation</subject><subject>Hyperthermia</subject><subject>Immunotherapy</subject><subject>Invasiveness</subject><subject>Medical prognosis</subject><subject>Methods</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Survival</subject><subject>Urine</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptUktP5SAUJpOZjEZdu5uQzMZZVKFQaFfGadTbxGQW81hKGHrwYlq4A63J_ffS-DYDCwjf43C-HIQOKTlmrCEnRnsDMdGKVJRX1Qe0WxJZFkI0_OOr-w46SOmW5MUYlUJ-RjtMNISUXO6i6y7htvuJNW6Dn6J2vndGTy54PAW82m4gTmuIozO4W_A7SBkfcLuGMSyI3mzx0ar7c95-w9pOEPH39rK40G6YI5zuo09WDwkOHs899Pvi_Fe7Kq5-XHbt2VVheN1MheVlaUqwWlBac7BgiNVWQF33QK01sqz6nkAJhklhQRuihWWy7quG6J5QtodOH3w3898RegPLXwe1iW7UcauCduot4t1a3YQ7RXMslDKeHY4eHWL4N0Oa1OiSgWHQHsKcVClrQZfQ6kz9-o56G-boc38Lq1oypuKFdaMHUM7bkAubxVSdSU4lz5WbzDr-DyvvHnLmwYN1-f2N4ORBYGJIKYJ9bpIStYyFejcWWfHldTbP_KchYPfvw7Mt</recordid><startdate>20230224</startdate><enddate>20230224</enddate><creator>Anastay, Vassili</creator><creator>Baboudjian, Michael</creator><creator>Masson-Lecomte, Alexandra</creator><creator>Lebacle, Cédric</creator><creator>Chamouni, Alexandre</creator><creator>Irani, Jacques</creator><creator>Tillou, Xavier</creator><creator>Waeckel, Thibaut</creator><creator>Monges, Arnaud</creator><creator>Duperron, Céline</creator><creator>Gravis, Gwenaelle</creator><creator>Walz, Jochen</creator><creator>Lechevallier, Eric</creator><creator>Pignot, Géraldine</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5282-9134</orcidid><orcidid>https://orcid.org/0000-0001-6935-3873</orcidid><orcidid>https://orcid.org/0000-0002-8215-2918</orcidid><orcidid>https://orcid.org/0000-0002-6321-9144</orcidid></search><sort><creationdate>20230224</creationdate><title>Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?</title><author>Anastay, Vassili ; Baboudjian, Michael ; Masson-Lecomte, Alexandra ; Lebacle, Cédric ; Chamouni, Alexandre ; Irani, Jacques ; Tillou, Xavier ; Waeckel, Thibaut ; Monges, Arnaud ; Duperron, Céline ; Gravis, Gwenaelle ; Walz, Jochen ; Lechevallier, Eric ; Pignot, Géraldine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-f422c2efa61184efec0faf6e88de1ffc725dd0e2ec376feac0a6f378d590ad013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BCG</topic><topic>BCG vaccines</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cellular biology</topic><topic>Chemotherapy</topic><topic>Comorbidity</topic><topic>Disease</topic><topic>Dosage and administration</topic><topic>Evaluation</topic><topic>Hyperthermia</topic><topic>Immunotherapy</topic><topic>Invasiveness</topic><topic>Medical prognosis</topic><topic>Methods</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Survival</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anastay, Vassili</creatorcontrib><creatorcontrib>Baboudjian, Michael</creatorcontrib><creatorcontrib>Masson-Lecomte, Alexandra</creatorcontrib><creatorcontrib>Lebacle, Cédric</creatorcontrib><creatorcontrib>Chamouni, Alexandre</creatorcontrib><creatorcontrib>Irani, Jacques</creatorcontrib><creatorcontrib>Tillou, Xavier</creatorcontrib><creatorcontrib>Waeckel, Thibaut</creatorcontrib><creatorcontrib>Monges, Arnaud</creatorcontrib><creatorcontrib>Duperron, Céline</creatorcontrib><creatorcontrib>Gravis, Gwenaelle</creatorcontrib><creatorcontrib>Walz, Jochen</creatorcontrib><creatorcontrib>Lechevallier, Eric</creatorcontrib><creatorcontrib>Pignot, Géraldine</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anastay, Vassili</au><au>Baboudjian, Michael</au><au>Masson-Lecomte, Alexandra</au><au>Lebacle, Cédric</au><au>Chamouni, Alexandre</au><au>Irani, Jacques</au><au>Tillou, Xavier</au><au>Waeckel, Thibaut</au><au>Monges, Arnaud</au><au>Duperron, Céline</au><au>Gravis, Gwenaelle</au><au>Walz, Jochen</au><au>Lechevallier, Eric</au><au>Pignot, Géraldine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-02-24</date><risdate>2023</risdate><volume>15</volume><issue>5</issue><spage>1455</spage><pages>1455-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>CIS of the bladder is associated with a high risk of progression. In the case of BCG failure, radical cystectomy should be performed. For patients who refuse or are ineligible, bladder-sparing alternatives are evaluated. This study aims to investigate the efficacy of Hyperthermic IntraVesical Chemotherapy (HIVEC) depending on the presence or absence of CIS. This retrospective, multicenter study was conducted between 2016 and 2021. Patients with non-muscle-invasive bladder cancer (NMIBC) with BCG failure received 6-8 adjuvant instillations of HIVEC. The co-primary endpoints were recurrence-free survival (RFS) and progression-free survival (PFS). A total of 116 consecutive patients met our inclusion criteria of whom 36 had concomitant CIS. The 2-year RFS rate was 19.9% and 43.7% in patients with and without CIS, respectively (
= 0.52). Fifteen patients (12.9%) experienced progression to muscle-invasive bladder cancer with no significant difference between patients with and without CIS (2-year PFS rate = 71.8% vs. 88.8%,
= 0.32). In multivariate analysis, CIS was not a significant prognostic factor in terms of recurrence or progression. In conclusion, CIS may not be considered a contraindication to HIVEC, as there is no significant association between CIS and the risk of progression or recurrence after treatment.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36900247</pmid><doi>10.3390/cancers15051455</doi><orcidid>https://orcid.org/0000-0001-5282-9134</orcidid><orcidid>https://orcid.org/0000-0001-6935-3873</orcidid><orcidid>https://orcid.org/0000-0002-8215-2918</orcidid><orcidid>https://orcid.org/0000-0002-6321-9144</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-02, Vol.15 (5), p.1455 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10001134 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | BCG BCG vaccines Bladder cancer Cancer Cancer therapies Care and treatment Cellular biology Chemotherapy Comorbidity Disease Dosage and administration Evaluation Hyperthermia Immunotherapy Invasiveness Medical prognosis Methods Multivariate analysis Patients Survival Urine |
| title | Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T03%3A45%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20CIS%20a%20Contraindication%20to%20Hyperthermic%20Intravesical%20Chemotherapy%20(HIVEC)%20after%20BCG-Failure?&rft.jtitle=Cancers&rft.au=Anastay,%20Vassili&rft.date=2023-02-24&rft.volume=15&rft.issue=5&rft.spage=1455&rft.pages=1455-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15051455&rft_dat=%3Cgale_pubme%3EA741740009%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785176716&rft_id=info:pmid/36900247&rft_galeid=A741740009&rfr_iscdi=true |